New regulation offers drug options for patients with rare, severe, or debilitating illnesses.
Brazil's deal to produce a generic version of a BMS AIDS drug has met with resistance — but the health ministry remains defiant. Hellen Berger reports.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial